Back to Peptides

NAD+

Mitochondrial Support

NAD+ (Nicotinamide Adenine Dinucleotide) is a vital coenzyme involved in redox reactions, DNA repair, and energy metabolism. NAD+ precursors and NAD+ IV/IM formulations are studied for their effects on aging, mitochondrial health, and cellular stress.

Reconstitute
3 mL BAC + 500mg vial
1667 mcg/unit
Daily Range
250–1000 mg Oral
daily
Standard Dose
500 mg
Cycle
4–8 weeks
then reassess
NAD+coenzymeenergy productionmitochondrial functionsirtuins

Dosing & Reconstitution Guide

In animal studies, NAD+ has been administered via IV or IP at 20–50 mg/kg. Oral NAD+ precursors (e.g., NR, NMN) have also been studied. Human injection protocols are experimental and unapproved.

Standard / Gradual Approach

500mg Vialstandard
PhaseDoseVolume
Week 150 mg30 units (0.30 mL)
Week 275 mg45 units (0.45 mL)
Weeks 3–8100 mg60 units (0.60 mL)
Weeks 9–12100 mg60 units (0.60 mL)
Weeks 13–16100 mg60 units (0.60 mL)

Standard / Gradual Approach

1000mg Vialstandard
PhaseDoseVolume
Week 150 mg15 units (0.15 mL)
Week 275 mg22.5 units (0.225 mL)
Weeks 3–8100 mg30 units (0.30 mL)
Weeks 9–12100 mg30 units (0.30 mL)
Weeks 13–16100 mg30 units (0.30 mL)

Protocol Summary

Oral: daily · Dose range 250–1000 mg with gradual titration
Intravenous (IV): once weekly · Dose range 250–1000 mg with gradual titration
Subcutaneous (SQ): 1-3 times per week · Dose range 25–100 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

25 mg - 100 mg 1–3 times per week as per Dr. Jatoi protocol

🧪 Quick Start

Vial Size
500 mg
BAC Water
3 mL
Concentration
166.7 mcg/unit
Starting Dose
50 mg (30 units (0.30 mL))
Maintenance Dose
100 mg (60 units (0.60 mL))

Potential Benefits & Use Cases

NAD+ in injectable form is not approved for therapeutic use. The information here is intended for research and educational purposes only.
Supports cellular energy production and mitochondrial function through NAD+ pool replenishment (preclinical)
Improves cognition in long-COVID patients (double-blind placebo-controlled trial with NR precursor, 2024) (human trial)
High-dose IV protocols (500–1,500 mg daily) reduce cravings and improve mood in substance use disorder (clinical case series)
Supports cognitive function and metabolic health at 100–300 mg/day (limited human data)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Serves as a coenzyme in redox reactions facilitating ATP production
→Acts as a substrate for sirtuins and PARPs
→Regulates circadian rhythms and immune responses
→Maintains NAD+/NADH and NADP+/NADPH redox balance
→Activates PGC-1α through SIRT1, promoting mitochondrial biogenesis
→Supports antioxidant response via FOXO and NRF2 activation

Lifestyle & Optimization

timing

IV infusions scheduled as tolerated. SubQ or oral precursors daily.

diet

Diet rich in NAD+ precursors (niacin, tryptophan). Minimize alcohol — PARPs deplete NAD+.

exercise

Regular exercise to upregulate NAD+ biosynthesis.

sleep

Sleep 7–9 hours. Stress reduction (PARPs deplete NAD+ under stress).

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
Pharmaceuticals (Basel) — Clinical evidence for targeting NAD+ therapeuticallyReference
Current Psychiatry Research and Reviews — NAD+ and enkephalinase infusions in substance use disorderReference
Frontiers in Aging Neuroscience — NAD+ in aging, metabolism, and neurodegenerationReference
PubMed — Intravenous NAD+ infusion increases human whole-blood NAD+Reference
PubMed (2023) — Safety and tolerability of IV NAD+ in healthy subjectsReference
Cell Metabolism — The science of NAD+ decline and metabolic diseaseReference
Nature Reviews Molecular Cell Biology — NAD+ metabolism and its roles in cellular processesReference

Side Effects & Safety

Common Side Effects

• Insomnia, anxiety, or fatigue if escalated too quickly; gradual titration advised
• Transient headache or flushing (dose-dependent)
• Doses exceeding 200–300 mg/day reserved for supervised use

🧮 Dose Calculator

Concentration
1666.7
mcg/unit
Draw Volume
—
units (0.000 mL)
For a 500 mcg dose, draw 0 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
Moderate to high systemic absorption depending on dose and formulation.
Oral Administration
Moderate
Half-Life
1-2 hours
Degradation
Metabolized by conversion to NADH as part of the cellular redox reactions
Tissue Specificity
Mitochondria
⚗️

Peptide Details

Molecular Weight
663.43
Formula
C21H27N7O14P2
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light and avoid freeze–thaw cycles